Racial Differences in Diabetic Cardiomyopathy, Genetics of HCM, Semaglutide vs. Tirzepatide for Weight Loss
Release Date:
In this week’s View, Dr. Eagle looks at the ARISE-HF trial that examined racial differences in diabetic cardiomyopathy. He then explores established and emerging implications of treatment of genetic hypertrophic cardiomyopathy (HCM). Finally, Dr. Eagle discusses the use of GLP-1 agonists, including semaglutide vs. tirzepatide for weight loss in adults with overweight or obesity. Subscribe to Eagle’s Eye View
Racial Differences in Diabetic Cardiomyopathy, Genetics of HCM, Semaglutide vs. Tirzepatide for Weight Loss